Pneumococcal Conjugate Vaccine
On this page
Direct answer
Pneumococcal conjugate vaccine (PCV) protects infants against invasive disease caused by Streptococcus pneumoniae by linking capsular polysaccharides to a protein carrier. That carrier produces a strong, memory-building response in infants, which the plain polysaccharide vaccine PPSV23 does not give reliably in young children. Routine infant schedules rely on the conjugate, while PPSV23 is reserved for older children at high risk.
What you must remember
- Mechanism: conjugation to a protein carrier makes the response T-cell dependent, so immunological memory forms in infancy.
- PCV products: PCV10 and PCV13 are the conjugate vaccines in use, and the national UIP introduced PCV13 in 2017 and expanded it nationwide in 2021.
- PPSV23: a polysaccharide vaccine covering 23 serotypes, not used before two years because the response is poor.
- Routine infant schedule: the UIP gives a 2+1 schedule at 6 weeks, 14 weeks and a 9-month booster, while the IAP schedule uses three primary doses plus a booster.
- Catch-up: children who start late receive fewer doses, with the number set by age at the first dose.
- High-risk indications: asplenia or sickle cell disease, HIV infection, nephrotic syndrome, chronic kidney disease and cochlear implants.
- PPSV23 in high-risk children: given from two years of age as a supplement, after a gap following the conjugate doses.
- Coverage limit: PCV protects only against the serotypes it contains, so non-vaccine serotypes can still cause disease.
Choosing the product by age and risk
A 14-month-old with sickle cell disease is due for pneumococcal protection, and the choice depends on age and risk. The table compares the two product types on the features examiners test.
| Feature | PCV (conjugate) | PPSV23 (polysaccharide) |
|---|---|---|
| Antigen | Polysaccharide linked to protein | Polysaccharide alone |
| Serotypes | 10 or 13 | 23 |
| Use under two years | Yes, routine | No |
| Memory response | Yes | Poor in young children |
The conjugate vaccine is the backbone of infant protection, while PPSV23 is an add-on for older high-risk children. Because PPSV23 cannot be relied on under two years, a 14-month-old with asplenia follows the conjugate schedule instead.
High-risk children who have completed the conjugate doses may still need PPSV23 later. The exact timing follows current national guidance, so the exam answer should name the principle rather than a fixed interval.
Pneumococcal infection in these children can cause pneumonia, bacteraemia and meningitis, and asplenia carries a particularly high risk of overwhelming infection. Fever in an asplenic child is therefore treated as an emergency, whatever the vaccination status.
Where the exam tries to catch you
Pneumococcal questions usually turn on age, serotype count and risk status.
- Trap: giving PPSV23 to a 6-month-old because it covers more serotypes Correct: polysaccharide vaccines do not give a reliable response before two years, so a conjugate vaccine is used.
- Trap: treating the routine schedule as complete protection for everyone Correct: high-risk children need extra doses, so the risk list must be checked before closing the schedule.
- Trap: choosing the vaccine by serotype count alone Correct: the age of the child decides the product, and the 23-valent vaccine is an older-child supplement.
Frequently asked questions
Why is PPSV23 not given to infants?
PPSV23 gives a poor response in children under two years, because polysaccharide antigens alone do not stimulate memory in young infants. Infants therefore receive a conjugate vaccine such as PCV, which induces a reliable response.
Which conditions make a child a high-risk candidate for pneumococcal vaccination?
High-risk children include those with asplenia or sickle cell disease, HIV infection, nephrotic syndrome, chronic kidney disease and cochlear implants. These children need pneumococcal protection beyond the routine infant schedule.
What is the catch-up schedule for a child who starts PCV after the first year?
Children who start late receive fewer doses than infants, and the number depends on their age at the first dose. The age-based catch-up table in the current national schedule should be used, because the exact doses vary by product.
How do PCV13 and PPSV23 differ in serotype coverage?
PCV13 covers 13 serotypes in conjugate form, while PPSV23 covers 23 serotypes in polysaccharide form. The conjugate is used for infants because the polysaccharide vaccine does not give a reliable response in young children.
Does PCV protect against all pneumococcal disease?
PCV protects only against the serotypes it contains, so it does not cover every pneumococcal strain. Children can still develop disease from non-vaccine serotypes, which is why surveillance of circulating serotypes matters.